NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage pharmaceutical company that entered the public markets in 2021 through a SPAC merger with Big Rock Partners Acquisition Corp., a blank-check company sponsored by Big Rock Partners. The transaction brought NRX, which focuses on treatments for central nervous system and life-threatening pulmonary conditions, into the publicly traded arena. The company has continued to operate as a post-merger public entity, advancing its pipeline of drug candidates targeting areas including bipolar depression and critical care. The August 2026 Form 8-K filing represents one of NRX's ongoing regulatory disclosures as a reporting company. For comprehensive SPAC deal history, filing data, and sponsor analytics on NRXP and hundreds of other transactions, sign up for full access at SpacDesk.